Abstract
BackgroundSacituzumab govitecan (SG) demonstrated an ORR of 27% and median OS of 10.5 months (Mo) in metastatic urothelial carcinoma (mUC) patients (pts) progressing after platinum chemotherapy and PD1/L1 inhibitor. The...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
